Spero Therapeutics Inc (SPRO) Stock Price, Quote & News

Company Profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candi...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 242 1600

Website: sperotherapeutics.com

Address:

675 Massachusetts Avenue, 14th Floor, Cambridge, United States

n44 Jan. 14 at 9:20 PM

$SPRO My thoughts are, GlaxoSmithKline would have transferred the 25 million dollars by now, I believe they are negotiating to buy the company outright at this point.

0 · Reply

n44 Jan. 14 at 9:14 PM

$SPRO Why would GSK give Spero 25 million dollars when they can just buy them for less than 300 million dollars less 25 million EQUALS 275. This is a bargain!!!!! When you figure how much money is needed to get an FDA approval this is bargain basement price to pay for GlaxoSmithKline.

1 · Reply

n44 Jan. 14 at 4:51 PM

$SPRO Will SPRO get priority review this time, Could the NDA be accepted before 60 days since it’s being resubmitted, will GSK pay the 25 million before or after the acceptance, is GSK going to buyout the rest of the shares of Spero or at what point does it make sense, so many questions to be answered and no answers, just reading the tea leaves.

1 · Reply

alan102 Jan. 14 at 12:56 PM

$SPRO Please continue with "1 forward 3 backward" steps, from 0.8 to 2.4 in 12 months.

0 · Reply

Inc82 Jan. 13 at 6:05 PM

$SPRO one step forward three steps backward

0 · Reply

mdboss Jan. 13 at 2:47 PM

$SPRO "Oral" is better! GSK will make Tebipenem a household name overnight.

1 · Reply

DDel Jan. 12 at 7:52 PM

$SPRO Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

1 · Reply

DDel Jan. 12 at 7:51 PM

$SPRO Don't need zacks list, gsk will acquire it all. Global antimicrobial resistance pandemic, gsk will get fda appr, gsk must have tebi. much more than just cUti's at stake. spro will be no more, its ticker will delist. i will stay until they turn the lights out and lock the door and hand the keys to gsk.

0 · Reply

Keep22 Jan. 11 at 4:26 AM

$SPRO except sales royalties, how much should GSK pay more to spero as milestones if things are going well from now?

2 · Reply

Zenlama Jan. 9 at 9:54 PM

$SPRO Or, they just stop paying for the service. Olg59 $SPRO Removed from Zacks ranking list -- badf sign! Bearish Jan 09, 2026 8:06 AM

1 · Reply

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

Nov 28, 2025, 8:00 AM EST - 6 weeks ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2025, 4:05 PM EST - 2 months ago

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

Nov 4, 2025, 4:05 PM EST - 2 months ago

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

Oct 21, 2025, 2:00 AM EDT - 3 months ago

PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Oct 14, 2025, 8:00 AM EDT - 3 months ago

Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

Aug 12, 2025, 7:32 PM EDT - 5 months ago

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:01 PM EDT - 5 months ago

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

Aug 5, 2025, 4:05 PM EDT - 5 months ago

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

Jun 11, 2025, 3:20 PM EDT - 7 months ago

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

May 28, 2025, 11:24 AM EDT - 8 months ago

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK

May 28, 2025, 7:00 AM EDT - 8 months ago

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

GSK

May 13, 2025, 4:01 PM EDT - 8 months ago

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 5, 2025, 8:00 AM EDT - 9 months ago

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

Apr 28, 2025, 4:01 PM EDT - 9 months ago

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

Mar 27, 2025, 8:31 PM EDT - 10 months ago

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:01 PM EDT - 10 months ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Mar 18, 2025, 8:00 AM EDT - 10 months ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

Feb 25, 2025, 10:15 AM EST - 11 months ago

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 11 months ago

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Jan 19, 2025, 8:00 AM EST - 1 year ago

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal

Jan 10, 2025, 7:00 AM EST - 1 year ago

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Nov 14, 2024, 4:05 PM EST - 1 year ago

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Oct 2, 2024, 4:30 PM EDT - 1 year ago

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Aug 9, 2024, 10:47 AM EDT - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

May 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

May 15, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

May 8, 2024, 8:00 AM EDT - 1 year ago

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

May 1, 2024, 4:07 PM EDT - 1 year ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2024, 11:37 AM EDT - 1 year ago

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Mar 13, 2024, 5:45 PM EDT - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:01 PM EDT - 2 years ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Mar 6, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Feb 28, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Feb 26, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

Jan 5, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Jan 2, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Nov 13, 2023, 7:05 PM EST - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:05 AM EST - 2 years ago

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 1, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Sep 20, 2023, 4:05 PM EDT - 2 years ago

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Jul 31, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Jul 5, 2023, 3:06 PM EDT - 2 years ago

Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK

n44 Jan. 14 at 9:20 PM

$SPRO My thoughts are, GlaxoSmithKline would have transferred the 25 million dollars by now, I believe they are negotiating to buy the company outright at this point.

0 · Reply

n44 Jan. 14 at 9:14 PM

1 · Reply

n44 Jan. 14 at 4:51 PM

1 · Reply

alan102 Jan. 14 at 12:56 PM

$SPRO Please continue with "1 forward 3 backward" steps, from 0.8 to 2.4 in 12 months.

0 · Reply

Inc82 Jan. 13 at 6:05 PM

$SPRO one step forward three steps backward

0 · Reply

mdboss Jan. 13 at 2:47 PM

$SPRO "Oral" is better! GSK will make Tebipenem a household name overnight.

1 · Reply

DDel Jan. 12 at 7:52 PM

$SPRO Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

1 · Reply

DDel Jan. 12 at 7:51 PM

0 · Reply

Keep22 Jan. 11 at 4:26 AM

$SPRO except sales royalties, how much should GSK pay more to spero as milestones if things are going well from now?

2 · Reply

Zenlama Jan. 9 at 9:54 PM

$SPRO Or, they just stop paying for the service. Olg59 $SPRO Removed from Zacks ranking list -- badf sign! Bearish Jan 09, 2026 8:06 AM

1 · Reply

mdboss Jan. 9 at 5:40 PM

$SPRO Why would anybody sell at $2.57 when you know your shares are easily worth over $20? It's absurd!

0 · Reply

buyandsold Jan. 9 at 2:41 PM

$SPRO reawakening SPR720 as inhalation and proceeding with SPR206 as internal dilutive program are the nightmares you dont want to wake up to.

1 · Reply

Olg59 Jan. 9 at 1:06 PM

$SPRO Removed from Zacks ranking list -- badf sign!

2 · Reply

mdboss Jan. 8 at 3:01 PM

$SPRO The line of sight to a HUMONGOUS price tag buyout by GSK has never been more clear than it is at this moment.

0 · Reply

DDel Jan. 7 at 7:23 PM

$SPRO GSK long and very

0 · Reply

mdboss Jan. 7 at 6:24 PM

$SPRO I don't want to speak out of turn but I think this is what it may look like when a global biopharma will be paying you big bucks for every single share you own. I have unwavering conviction and an immense position in this company! Best wishes to all longs as we witness this very unusual behavior for SPRO! Tick tock. Tick tock!!!!!!

1 · Reply

David_Stockett1836 Jan. 7 at 4:51 PM

$SPRO is this finally getting legs? Thankfully we’ve had plenty of time to load up.

0 · Reply

DDel Jan. 5 at 7:56 PM

$SPRO $25M milestone payment in Q1 is chump change for GSK, they will buy it all, instead. spro ends. they could have easily paid it in Q4, but elected not to. imo.

0 · Reply

mdboss Jan. 5 at 4:40 PM

$SPRO I have no idea if this will close above $2.40, but if it does we have a handsome bullish golden cross establishing itself. Here's hoping for lots of green ticks in 2026!

0 · Reply

Zordo Jan. 5 at 12:01 AM

$SPRO ...I just find this interesting: "The Vanguard Extended Market ETF (VXF) is the largest ETF holder of SPRO, with approximately 516.11K shares. This ETF is part of the U.S. stock market and holds around 561.6K shares in the U.S. ETF market. "

1 · Reply

mdboss Jan. 4 at 12:52 PM

$SPRO Tebi promises to bring in billions of dollars each year to GSK over the next decade. Everybody here is consumed by milestones and royalty details of the deal inked over 3 years ago. Tebi is so much bigger than the bullshit terms of that generic deal. The big idea here is the creation of a new oral class of antibiotics to battle resistant organisms. GSK and Spero share the same vision and have enjoyed a close productive working partnership for many years. We know GSK anticipates sales each year in the billions and I believe Spero will get the recognition and valuation it ultimately deserves. The base case for a reasonable Spero buyout is a billion dollars and I'm hoping it will be several billion. I'm in this to win this and I'm greedy and I intend to milk every dollar I can get out of this investment. You all need to think much much bigger because we are playing in a sand box with future earnings in the BILLIONS!!!!!

0 · Reply

Keep22 Jan. 3 at 1:34 AM

$SPRO so if commercialized, how big Tebi 's expected sales in USA and Europe? Can it be over 2billion pounds at peak? Does GSK expect like that? then at peak year, royalties can be 200m dollars per year. Correct me if I am wrong.

1 · Reply

Market Cap	138.03M
Revenue (ttm)	47.98M
Net Income (ttm)	-68.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-142.91%
Debt to Equity Ratio	0.00

Volume	215,600
Avg Vol	351,898
Day's Range	N/A - N/A
Shares Out	56.34M
Stochastic %K	59%
Beta	1.46
Analysts	Sell
Price Target	$4.50